Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

PCTEL (PCTI) To Report Q4 Earnings: What's In The Offing?

Published 03/03/2020, 07:03 AM
Updated 07/09/2023, 06:31 AM
COST
-
PCTI
-
COO
-
BURL
-

PCTEL, Inc. (NASDAQ:PCTI) is scheduled to report fourth-quarter 2019 results on Mar 5, after the closing bell. In the last reported quarter, the company delivered a positive earnings surprise of 16.7%, beating the Zacks Consensus Estimate by 2 cents. Notably, PCTEL topped the Zacks Consensus Estimate for earnings in the trailing four quarters, the beat being 150.6%, on average.

The Bloomingdale, IL-based company is expected to have recorded higher aggregate revenues on a year-over-year basis in the fourth quarter, primarily driven by 5G scanning receiver business. It is well positioned to benefit from the number of industrial IoT applications together with robust market for its antenna solutions.

Factors at Play

During the fourth quarter, PCTEL announced new testing capabilities to support 4G/5G Dynamic Spectrum Sharing (DSS) and accelerate 5G New Radio rollouts. DSS testing is available on new and existing HBflex and IBflex scanning receivers. This is expected to get reflected positively in the upcoming results.

The company added Digital Mobile Radio signal quality measurements to its public safety network testing solution. With this, the efficient pass/fail testing system can be applied to a broad range of public and private critical communications networks. PCTEL’s public safety network testing solution reduces testing and reporting time by more than 50%.

PCTEL expanded its Industrial IoT portfolio adding access points, sensor communication and radio modules to its market-leading line of purpose-built antennas. It launched a new antenna that combines precision multi-constellation Global Navigation Satellite System with high performance LTE, sub-6 GHz 5G, Bluetooth and Wi-Fi connectivity. The company’s performance is expected have benefited from these positives.

For the December quarter, the Zacks Consensus Estimate for total revenues stands at $24 million, implying a rise of 14.3% from the year-ago quarter’s reported figure. Adjusted earnings per share are pegged at 12 cents, indicating an increase of 300% from the prior-year quarter’s reported figure.

What Our Model Says

Our proven model doesn’t predict an earnings beat for PCTEL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here as you’ll see below:

Earnings ESP: PCTEL’s Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% as both are pegged at 12 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

PCTEL, Inc. Price and EPS Surprise

Zacks Rank: PCTEL currently carries a Zacks Rank #2.

Stocks to Consider

Here are some companies that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:

Burlington Stores, Inc. (NYSE:BURL) is slated to release quarterly results on Mar 5. It has an Earnings ESP of +0.02% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Costco Wholesale Corporation (NASDAQ:COST) is scheduled to release results on Mar 5. The company has an Earnings ESP of +0.20% and carries a Zacks Rank #2.

The Cooper Companies, Inc. (NYSE:COO) has an Earnings ESP of +0.63% and a Zacks Rank of 3. The company is set to report results on Mar 5.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



The Cooper Companies, Inc. (COO): Free Stock Analysis Report

Costco Wholesale Corporation (COST): Free Stock Analysis Report

Burlington Stores, Inc. (BURL): Free Stock Analysis Report

PCTEL, Inc. (PCTI): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.